Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Complement factor 9 deficiency in serum of human neonates.

H A Lassiter1, S W Watson, M L Seifring

  • 1Department of Pediatrics, University of Louisville School of Medicine, Kentucky.

The Journal of Infectious Diseases
|July 1, 1992
PubMed
Summary

Neonatal sera have lower concentrations of complement factor C9 (C9), leading to inefficient killing of Escherichia coli. Supplementing with C9 and IgG improved bacterial killing in neonates.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nitrogen acquisition and resource allocation strategies in temperate seagrass Zostera nigricaulis: Uptake, assimilation and translocation processes.

Scientific reports·2018
Same author

Ventilation in India.

The Indian medical gazette·2017
Same author

Ventilation in India.

The Indian medical gazette·2017
Same author

Ventilation in India.

The Indian medical gazette·2017
Same author

Inhibition of IκB kinase by thalidomide increases hepatitis C virus RNA replication.

Journal of viral hepatitis·2012
Same author

Cleavage of intracellular hepatitis C RNA in the virus core protein coding region by deoxyribozymes.

Journal of viral hepatitis·2006

Area of Science:

  • Immunology
  • Neonatal Immunology

Background:

  • Neonates exhibit a less developed immune system compared to adults.
  • The complement system, particularly the terminal pathway involving complement factor C9 (C9), plays a crucial role in innate immunity and bacterial clearance.

Purpose of the Study:

  • To investigate the concentration and functional activity of C9 in neonatal sera.
  • To assess the bactericidal capacity of neonatal sera against Escherichia coli.
  • To determine the effect of supplemental C9 and IgG on neonatal serum bactericidal activity.

Main Methods:

  • Quantification of C9 serum concentrations in mothers and neonates.
  • Assessment of serum bactericidal activity against Escherichia coli O7w:K1:NM.
  • Evaluation of the impact of exogenous C9 and IgG supplementation on bacterial killing and C9 deposition.

Related Experiment Videos

Main Results:

  • Neonatal sera showed significantly lower C9 concentrations (less than 42 µg/ml) compared to maternal sera (260 ± 47 µg/ml).
  • Neonatal sera demonstrated reduced bactericidal activity against E. coli, with only 3 of 14 samples significantly reducing bacterial survival.
  • Supplementation with C9 enhanced the bactericidal capacity of neonatal sera, and supplemental IgG further potentiated C9 deposition and bacterial killing.

Conclusions:

  • Neonatal sera possess diminished concentrations of C9, contributing to impaired bactericidal function against E. coli.
  • Exogenous C9 can restore and enhance the bactericidal activity of neonatal sera.
  • The combined presence of C9 and IgG is crucial for effective bacterial clearance in neonates, highlighting potential therapeutic targets.